Background-In nondiabetic patients with ST-segment-elevation myocardial infarction, acute hyperglycemia is associated with adverse outcome. Whether this association is due merely to hyperglycemia as an acute stress response or whether longer-term glycometabolic derangements are also involved is uncertain. It was our aim to determine the association between both acute and chronic hyperglycemia (hemoglobin A 1c [HbA 1c ]) and outcome in nondiabetic patients with ST-segment-elevation myocardial infarction.
dial infarction are limited. 8 -10 The aim of the present study was to assess the prognostic impact of both admission HbA 1c and glucose levels in a large population of patients without known diabetes mellitus who were treated with PCI for ST-segment-elevation myocardial infarction (STEMI).
Methods
We performed an observational study including all consecutive patients admitted with ST-elevation myocardial infarction to 2 large hospitals (Isala Klinieken, Zwolle, and the University Medical Center Groningen, Groningen) in the Netherlands. The inclusion period was January 2004 to January 2009 for the hospital in Zwolle and January 2005 to April 2009 for the hospital in Groningen. During these time frames, HbA 1c and admission glucose were routinely measured on admission in all STEMI patients.
ST-segment elevation myocardial infarction was defined as complaints of chest pain with ECG signs compatible with acute myocardial infarction (ST-segment elevation Ͼ2 mm in precordial leads and Ͼ1 mm in limb leads). 11 All patients were directly transported to the catheterization laboratory on arrival, and acute coronary angiography was performed with subsequent PCI when indicated as part of the routine treatment for all STEMI patients in these institutions. The interventional strategy was at the operator's discretion. All patients were pretreated with aspirin, heparin, and clopidogrel during transportation to the hospital, or these drugs were administered at the emergency ward. 12 
Data Collection
Patient characteristics were recorded on admission with either case record forms or a computer-based database. Ischemic time was defined as the time between symptom onset and first balloon inflation. Thrombolysis in Myocardial Infarction (TIMI) flow was scored according to the TIMI flow grading system before and after PCI. 13 Myocardial blush grade was defined as previously described. 14 Successful PCI was defined as TIMI grade 3 flow with myocardial blush grade 2 to 3 after PCI. Myocardial infarct size was measured by peak creatinine kinase level in the first 24 hours after admission. Diabetes mellitus was defined as known diabetes mellitus on admission, which was treated with diet, oral glucose-lowering medication, and/or insulin. Clinical follow-up was performed by telephone contact (with either the general practitioner or the patient) or through coupling of municipal mortality records. Follow-up was performed by independent research nurses not involved in patient treatment. The HbA 1c levels were measured on the Primus Ultra 2 affinity chromatography-HPLC (Primus Diagnostics, Kansas City, MO) in Zwolle with a within-run coefficient of variation of Ͻ0.5% and on a Roche COBAS Integra 800 closed-tube system in Groningen. Both devices report the same reference normal values of 4.0% to 6.0% in nondiabetics. Glucose levels were measured with a Modular device (Roche Diagnostics) in Zwolle and with a Radiometer ABL 700/800 series analyzer (Radiometer Copenhagen) in full-blood arterial samples or in sodium fluoride-containing tubes with the Roche Modular analyzer in Groningen. During the study period, reference values did not change, and yearly numeric quality control data revealed that the coefficient of variation remained Ͻ2% during this time period. Both glucose measurements and HbA 1c measurements were compared between the 2 centers. For optimal analysis, HbA 1c levels were transformed linearly to match those of Zwolle. Measurements from the Zwolle hospital were used as the reference because the central laboratory of this center has extensive experience with the glucose and HbA 1c assays and because this center contributed the most patients. The HbA 1c values from the University Medical Center Groningen were corrected with a factor of 0.95 for optimal matching with the patients from Zwolle. Glucose distributions were similar between the 2 centers, and no adjustment was necessary.
To maintain a uniform patient population with genuine STEMI, specific inclusion and exclusion criteria were applied. To avoid inclusion of patients with a false diagnosis of STEMI (eg, owing to pericarditis), only patients in whom a PCI was performed in the acute setting were included. Patients who presented after an out-of-hospital cardiac arrest were also excluded because prognosis in these patients is driven primarily by neurological outcome. There were no exclusion criteria with regard to age, sex, ischemic time, cardiac history, or renal function.
Statistical Analysis
For the analysis, patients with known diabetes mellitus were excluded. The primary end point was long-term mortality (maximum follow-up available per patient). Secondary end points were 1-year mortality and enzymatic infarct size. Patient groups were created according to quartiles of admission HbA 1c and glucose, referred to as interquartile range (IQR) 1 to 4. Continuous data were summarized and are given as median values with corresponding IQR or as mean values with corresponding SD, and dichotomous data are given as counts and percentages. Mortality data were compared by use of either 2 test (30-day and 1-year mortality) or log-rank analysis (long-term mortality) for comparison of Kaplan-Meier actuarial survival curves. Means between groups were compared by use of independent-samples t tests (ANOVA polynomial linear term) or Mann-Whitney U tests (Kruskal-Wallis) when appropriate.
Kaplan-Meier curves were constructed for overall mortality using the log-rank statistic for comparisons between groups. In multivariate analysis (Cox regression using backward stepwise variable selection methods), the association between HbA 1c , glucose and outcome (long-term mortality) was adjusted for age, sex, and all predictors of mortality (prior coronary artery disease, hypertension, active smoking, renal function, systolic blood pressure on admission, heart rate on admission, ischemic time, multivessel coronary artery disease, anterior infarction, TIMI flow before PCI, TIMI flow after PCI). To investigate the effect of glucose and HbA 1c on early and late mortality, a secondary univariate landmark analysis was performed excluding mortality within 30 days and resetting follow-up times after this period.
All statistical tests were performed with SPSS 12.0. A value of PϽ0.05 was considered statistically significant.
Results
From January 2004 until April 2009, a total of 5373 patients were included: 3369 in Zwolle and 2004 in Groningen. As defined by the inclusion criteria, all patients were treated with primary PCI. A total of 598 patients (11%) had diabetes mellitus on admission. Diabetic status was missing for 77 patients (1.4%), and these patients were excluded from the main analysis. Of the remaining 4698 patients included in the present analysis, HbA 1c on admission was not available in 522 patients (11%). Final analysis was therefore performed on 4176 patients.
Mean age (62Ϯ13 versus 63Ϯ13 years; Pϭ0.17) and distribution of sex (male, 74% in both centers; Pϭ0.82) and median HbA 1c levels (5.60 [IQR, 5.40 to 5.80] versus 5.54 [IQR, 2.26 to 5.92]; Pϭ0.75) were comparable between patients included from Zwolle and Groningen. Other baseline and angiographic characteristics were also comparable between Zwolle and Groningen, except the presence of multivessel disease (45.8% versus 54.9%; PϽ0.001). For the total group, the mean follow-up period was 3.3Ϯ1.5 years. Thirtyday follow-up was complete in 99.9% of the patients; 1-year follow-up was complete in 99.6% of the patients. One-year mortality was 4.7% and long-term mortality was 10%.
Patients were divided on the basis of admission HbA 1c quartiles (IQR 1, Յ5.35%; IQR 2, 5.36% to 5.54%; IQR 3, 5.55% to 5.80%; and IQR 4, Ն5.81%). Baseline and angiographic characteristics are shown in Table 1 . Patients with higher HbA 1c levels were older, were more often female, and more often had a prior history of coronary artery disease. There was a strong correlation between admission HbA 1c and admission glucose level (PϽ0.001). Clinical outcome (30day mortality, 1-year mortality, and infarct size) is displayed in Table 2 . With increasing HbA 1c levels, there was an increase in the prevalence of multivessel disease, and there was a modest increase in PCI failure in the upper quartile of HbA 1c . One-year mortality was significantly higher with increasing HbA 1c levels (Pϭ0.001). Infarct size, as measured by peak creatinine kinase, was not correlated with HbA 1c levels. Patients were also divided according to admission glucose quartiles (IQR 1, Յ6.9 mmol/L; IQR 2, 7.0 to 8.1 mmol/L; IQR 3, 8.2 to 9.5 mmol/L; and IQR 4, Ն9.6 mmol/L) (for mg/dL, multiply by 18). Baseline and angiographic characteristics are shown in Table 3 . Higher admission glucose was associated with more frequent presence of multivessel disease, less frequent TIMI 3 flow on admission, and a lower rate of successful PCI. There was a clear association between the use of an intra-aortic balloon pump and high admission glucose (PϽ0.001). Clinical outcome is shown in Table 2 . Both 30-day mortality and long-term mortality were significantly associated with higher glucose levels (PϽ0.001). A U shape was present with regard to admission glucose and mortality in which patients with low admission glucose (IQR 1, Յ6.9 mmol/L) had a slightly higher mortality than patients with normal admission glucose (IQR 2, 7.0 to 8.1 mmol/L). There was a significant positive correlation between admission glucose and infarct size, measured by peak creatinine kinase level (PϽ0.001).
One-year mortality in patients with known diabetes mellitus (nϭ598) was 11.0% compared with 4.6% in the patients without known diabetes mellitus on admission (nϭ4176; PϽ0.001). For patients without known diabetes mellitus on admission, clinical outcome is presented in Table 2 stratified according to admission HbA 1c and glucose IQR. Survival curves for admission HbA 1c and glucose IQR for patients without known diabetes mellitus on admission are presented in Figures 1 and 2 , respectively. Elevated HbA 1c levels were generally associated with increased long-term mortality regardless of admission glucose level, although the difference in patients with admission glucose levels in the highest quartile was not statistically significant (Figure 3 ). To investigate the effect of glucose and HbA 1c on early versus late mortality, we also performed an analysis after excluding patients who died within the first 30 days. Glucose was no longer associated with long-term mortality (Pϭ0.09), whereas admission HbA 1c remained significantly associated with long-term mortality (PϽ0.001). After multivariate analysis correcting for baseline characteristics, hemodynamic parameters, and angiographic findings, HbA 1c (hazard ratio per IQR, 1.2; 95% confidence interval, 1.0 to 1.3), but not admission glucose, was significantly associated with long-term mortality. Significant predictors are presented in Table 4 .
Discussion
Our study shows that in STEMI patients without known diabetes mellitus, both short-and long-term abnormalities in glucose control are associated with long-term mortality. Both parameters reflect different patient populations, and their association with outcome is probably due to different mechanisms. Measurement of HbA 1c levels in nondiabetic patients may improve risk assessment in patients presenting with acute STEMI.
Although acute hyperglycemia on admission and during hospital stay has clearly been associated with adverse out-come in patients with acute myocardial infarction, 5, 15, 16 the prognostic value of admission HbA 1c levels in this population has been less well established. 8 -10 Our study shows that admission HbA 1c levels are associated with higher mortality in a nondiabetic STEMI population treated with primary PCI.
Several factors may play a role in the demonstrated association between HbA 1c levels and adverse outcome. Increasing HbA 1c levels were clearly associated with adverse baseline characteristics such as a higher cardiovascular risk profile, explaining part of the increase in long-term mortality. In addition, it is conceivable that part of the association between long-term abnormalities in glucose control and outcome is due to the same complex mechanisms responsible for the adverse association between overt diabetes mellitus and cardiovascular outcome. Indeed, it has been well established that the excess risk for developing coronary artery disease is not limited to patients with diabetes mellitus but also is present in impaired fasting glucose, impaired glucose tolerance, and other states of insulin resistance. [17] [18] [19] [20] Our findings indicate that these factors continue to play a negative role after cardiovascular disease has become clinically overt.
Because the number of patients with long-term abnormalities in glucose control and subsequent cardiovascular sequelae is likely to increase in the future decades, more tailored therapy should be investigated in this patient population. The European guidelines on diabetes mellitus, prediabetes, and cardiovascular disease recommend that people at high risk for type 2 diabetes mellitus should receive lifestyle counseling and, if needed, pharmacological therapy to reduce their risk of developing overt hyperglycemia and type 2 diabetes mellitus but especially to prevent or slow the development of cardiovascular disease. 21, 22 This approach could also be encouraged in our patient population, and it may alter prognosis, although the benefits with regard to slowing the progression to diabetes mellitus still have to be elucidated. However, it is known that the overall increase in cardiovascular risk in patients with diabetes mellitus or milder abnormalities in glucose levels is not explained by abnormalities in glucose or HbA 1c alone, which is an important consideration in designing prevention efforts.
Specific strategies targeting the acute glucose abnormalities in STEMI may be beneficial in theory, but results of acute interventions in glucose metabolism in patients with acute coronary syndromes have proved disappointing. [23] [24] [25] More concise ideas regarding therapeutic implications and options have yet to evolve.
Hyperglycemia in STEMI patients was strongly associated with increased mortality. Although there is a clear correlation between admission glucose and HbA 1c levels, they appear to represent related but different phenomena. Patients with elevated glucose levels have larger myocardial infarctions and less frequently have open infarct-related vessels on the initial angiogram. They also need hemodynamic support of an intra-aortic balloon pump more often, probably reflecting severe hemodynamic stress caused by pump failure. Indeed, after correction for hemodynamic parameters such as blood pressure, heart rate on admission, and angiographic findings, glucose was no longer independently associated with longterm mortality.
In comparison, patients with elevated HbA 1c levels particularly had high-risk baseline characteristics such as a higher prevalence of prior cardiovascular disease and a higher prevalence of renal dysfunction. In these patients, there was no increase in infarct size, nor did they need more mechanical support of an intra-aortic balloon pump. So, it appears that the mechanisms by which both glucose and HbA 1c are linked to outcome are distinct and may even be partially independent from each other. Indeed, in our study, glucose was particularly associated with mortality within 30 days. When patients who died within 30 days were excluded, glucose lost its association with mortality, whereas HbA 1c remained a strong predictor of future mortality. So, in contrast to HbA 1c , the negative impact of elevated admission glucose on prognosis is particularly reflected by early mortality. This probably reflects the acute stress of hemodynamically unstable patients with higher glucose levels compared with the more general increase in cardiovascular risk associated with higher HbA 1c levels. 5 Recently, a prospective cohort study showed that in a nondiabetic general population, an elevated HbA 1c level is a risk factor for the development of cardiovascular events independently of fasting glucose. 3 Our data suggest that HbA 1c may also be used to assess cardiovascular risk in a nondiabetic population after STEMI. Thus, the importance of elevated HbA 1c in nondiabetics can be generalized from an indicator of primary risk to secondary risk. Besides providing prognostic information, routine HbA 1c measurement in STEMI patients may help to identify patients with undetected diabetes mellitus or those at increased risk for developing diabetes mellitus in the future. 3
Study Limitations
This was a retrospective study without cause-specific mortality. Diabetes mellitus was defined as known diabetic status on admission. It is well known that a number of STEMI patients have undetected diabetes mellitus, and they were not excluded in our study. 15, 26 Indeed, when the HbA 1c cutoff value of Ն6.5% as suggested by the American Diabetes Association was used, Ϸ5% of our population could readily be diagnosed with diabetes mellitus on admission (undiagnosed diabetes mellitus), and they were not excluded from the main analysis. 27 However, because there was a stepwise increase in mortality with increasing HbA 1c levels starting from the lowest to the highest quartile, we believe that our findings are not solely attributable to the number of patients with undetected diabetes mellitus. It is conceivable that some subjects within the higher HbA 1c quartiles may have progressed to overt diabetes mellitus within the follow-up period, which would also adversely affect long-term prognosis. Because we had no data on the occurrence of this diagnosis or the start of glucose-lowering medication during the follow-up period, the magnitude of this phenomenon was unknown in our study. Another limitation might be that although admission glucose will be responsive to the acute stress associated with an STEMI, many other factors may contribute to the variability of nonfasting glucose levels.
Conclusions
Both elevated admission HbA 1c and glucose were associated with an adverse prognosis in nondiabetic patients with STelevation myocardial infarction treated with primary PCI. The HbA 1c and glucose levels reflect different patient populations, and their association with outcome is probably due to different mechanisms. High admission glucose is associated with a more hemodynamically unstable patient group with a larger infarct size and high early mortality. Elevated HbA 1c is associated with more adverse baseline characteristics and a more gradual higher mortality over time. Close follow-up of these patients seems warranted. More research is needed to better describe and understand these findings, and, more important, to assess and develop feasible treatment options.
